𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients

✍ Scribed by Fiegl, M.; Stauder, R.; Steurer, M.; Mian, M.; Hopfinger, G.; Brychtova, Y.; Skrabs, C.; Zabernigg, A.; Schmid, F.; Haslbaur, F.; Winder, G.; Walder, A.; Lang, A.; Voskova, D.; Greil, R.; Mayer, J.; Gastl, G.

Book ID
121574788
Publisher
Springer
Year
2013
Tongue
English
Weight
300 KB
Volume
93
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Routine clinical use of alemtuzumab in p
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia : A nation-wide retrospective study in Austria
✍ Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 250 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono

Subcutaneous Alemtuzumab in Fludarabine-
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
✍ Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; πŸ“‚ Article πŸ“… 2009 πŸ› American Society of Clinical Oncology 🌐 English βš– 170 KB

## Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. ## Patients and Methods One hundred nine patients